Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed its Form 10-K for the fiscal year ended December 31, 2022, covering the full year rather than a standalone fourth quarter. West manufactures injectable-drug containment, packaging and delivery systems, and provides contract manufacturing, analytical laboratory and integrated services. Operations are organized into Proprietary Products and Contract-Manufactured Products.
- International sales represented 55.4% of consolidated net sales.
- Approximately 10,700 employees were employed globally at year-end.
- The ten largest customers represented 45.6% of sales; no individual customer exceeded 10%.
Financial Performance and Position
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Net sales | $2,886.9 million | $2,831.6 million | 2.0% |
| Gross profit | $1,136.2 million | $1,175.8 million | (3.4%) |
| Gross margin | 39.4% | 41.5% | (2.1) points |
| Operating profit | $734.0 million | $752.3 million | (2.4%) |
| Operating margin | 25.4% | 26.6% | (1.2) points |
| Net income | $585.9 million | $661.8 million | (11.5%) |
| Diluted EPS | $7.73 | $8.67 | (10.8%) |
| Cash flow from operations | $724.0 million | $584.0 million | 24.0% |
| Capital expenditures | $284.6 million | $253.4 million | 12.3% |
Adjusted operating profit was $762.0 million, with an adjusted operating margin of 26.4%, compared with $762.4 million and 26.9% in 2021. Adjusted net income was $650.0 million and adjusted diluted EPS was $8.58, versus $655.2 million and $8.58, respectively, in 2021.
- Proprietary Products sales increased 3.9% to $2,406.8 million; sales excluding currency effects increased 9.8%. Segment operating profit declined 1.5% to $784.4 million.
- Contract-Manufactured Products sales declined 6.7% to $480.4 million; sales excluding currency effects declined 2.0%. Segment operating profit declined 10.1% to $60.4 million.
- Sales price increases contributed approximately $106 million, while unfavorable foreign currency translation reduced reported sales by approximately $162.6 million.
- Inflation, labor and overhead costs, and increased plant spending reduced gross margins, particularly in Proprietary Products. SG&A declined 12.7% to $316.9 million, primarily due to lower incentive compensation and stock-based compensation effects.
Liquidity, Debt and Capital Allocation
| Balance-sheet metric | December 31, 2022 | December 31, 2021 |
|---|---|---|
| Cash and cash equivalents | $894.3 million | $762.6 million |
| Debt | $208.9 million | $253.0 million |
| Working capital | $1,400.5 million | $1,147.9 million |
| Equity | $2,684.9 million | $2,335.4 million |
- West had no borrowings under its $500 million revolving credit facility and reported $497.6 million of available capacity, including letters of credit.
- Debt declined primarily due to repayment of the $42 million Series A notes and scheduled term-loan repayments. Debt maturities include $2.2 million in 2023, $134.0 million in 2024 and $73.0 million in 2027.
- The company was in compliance with debt covenants and stated that cash, operating cash flow and credit availability should cover foreseeable liquidity needs.
- West paid $54.1 million of dividends and repurchased $202.8 million of common stock, or 563,334 shares, during 2022. In February 2023, the board authorized an additional $1.0 billion repurchase program.
Material Changes Versus the Prior Comparable Period
- Reported sales grew modestly despite a $162.6 million unfavorable currency impact and lower COVID-19-related activity. Proprietary Products benefited from growth in high-value offerings, while Contract-Manufactured Products was affected by weaker diagnostic-device component sales.
- Gross margin fell 2.1 percentage points because of approximately $85 million of inflationary headwinds in Proprietary Products, increased plant spending and higher labor and transportation costs.
- Net income and diluted EPS declined primarily because of lower operating profit, higher tax expense and a $52.2 million pension settlement charge associated with terminating the U.S. qualified defined benefit plan.
- Operating cash flow increased $140.0 million, reflecting improved working-capital management, particularly in accounts receivable and inventory.
- Capital expenditures increased to support additional manufacturing capacity and customer demand.
Guidance, Outlook, Commentary and Unusual Items
The filing text does not provide a clear numerical 2023 revenue or earnings guidance figure. Management stated that short-term performance may remain volatile because of inflation, supply-chain constraints, foreign exchange and other macroeconomic conditions. The company expects its cash resources and credit availability to support foreseeable liquidity requirements.
- A December 2022 restructuring plan is expected to generate total charges of approximately $25 million to $27 million and annualized savings of $22 million to $24 million. The plan is expected to be implemented over up to twelve months.
- 2022 restructuring charges were $23.8 million, including $15.3 million of asset-related charges and $8.7 million of severance and post-employment benefits.
- The $52.2 million pension settlement charge was largely nonrecurring and relieved the historical U.S. pension-plan balance-sheet position; the plan was settled through a group annuity contract in August 2022.
- Other 2022 items included a $3.5 million cost-investment impairment, $5.7 million of tax expense from Pennsylvania tax-law changes, and $19.8 million of reserves for unrecognized tax benefits.
- Key risks include inflation and raw-material costs, reliance on single-source suppliers, manufacturing or supply-chain disruptions, foreign currency exposure, cyberattacks, regulatory and product-liability matters, pricing pressure, dependence on injectable-drug markets, and the timing and success of new-product commercialization.
- The company licenses important technologies from Daikyo under agreements expiring in 2027; early termination or nonrenewal could adversely affect the business.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. Income taxes were identified as the critical audit matter.
Important Facts for Investors to Verify
- Whether pricing actions and productivity improvements offset inflation, labor, energy and raw-material costs sufficiently to restore gross margins.
- The pace of recovery or further deterioration in Contract-Manufactured Products, particularly diagnostic-device demand.
- Progress, cash costs and realized savings from the 2022 restructuring plan.
- The sustainability of operating cash flow as capital expenditures remain elevated for capacity expansion.
- The timing and funding impact of 2024 and 2027 debt maturities, as well as utilization of the revolving credit facility.
- The scale and valuation implications of the newly authorized $1.0 billion share-repurchase program.
- Potential effects of foreign exchange movements, international tax examinations and $36.5 million of gross unrecognized tax benefits.
- Supply continuity for critical single-source raw materials and the impact of geopolitical, public-health and cybersecurity events.